Charles River and Captain T Cell sign vector production agreement
18 Jun 2024
Cell TherapyGene TherapyImmunotherapy
Preview
Source: Pharmaceutical Technology
To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector production expertise of Charles River. Credit: Hakat / Shutterstock.
Preview
Source: Pharmaceutical Technology
Charles River Laboratories has entered an agreement with German company Captain T Cell to focus on the production of plasmid DNA and retrovirus vectors for gene-modified cell therapy.
The collaboration is part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program, which provides Captain T Cell with access to contract development and manufacturing organisation (CDMO) expertise and advisory services.
The alliance is a strategic move for Captain T Cell as it prepares to manufacture a TCR-T cell therapy aimed at treating solid tumour patients in Phase I clinical trials.
Captain T Cell develops treatment options for solid tumours, aiming to extend the reach of T cell immunotherapies to new patient groups.
Its approach involves creating T cells equipped with tumour-specific T cell receptors (TCRs) with improved persistence and the ability to withstand the challenging tumour microenvironment of hard-to-treat solid tumours.
See Also:Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval
Preview
Source: Pharmaceutical Technology
To advance its gene-modified cell therapy to clinical stages, Captain T Cell will utilise the plasmid and viral vector production expertise of Charles River, which has been refined to aid CGT developers from pre-clinical through commercialisation.
Charles River has expanded its cell and gene therapy portfolio through acquisitions and facility expansions to streamline complex supply chains and cater to the increasing demand for plasmid DNA, viral vector and cell therapy services.
Charles River global manufacturing corporate senior vice-president Kerstin Dolph stated: “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy.
“Charles River has decades of success reliably manufacturing plasmid DNA, viral vectors and cell therapies, helping to safeguard our customer programmes and bring potential therapies to patients with limited options.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Thank you.You will receive an email shortly. Please check your inbox to download the Whitepaper.
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.